... oral mucositis in patients receiving high-dose melphalan. or BEAM conditioning chemotherapy—European Blood. and Marrow Transplantation Mucositis Advisory Group.
... melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. N. BlijlevensM. Schwenkglenks +12 authors. S ...
... melphalan or BEAM conditioning chemotherapy--European blood and marrow transplantation mucositis advisory group. ... patients receiving high-dose melphalan ...
Jan 4, 2017 · Toxicity of the oral and gastrointestinal mucosa induced by high-dose melphalan is a clinical challenge with no documented prophylactic ...
Ensuring accurate oral mucositis assess- ment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis. Audit. Eur J Oncol Nurs ...
Jul 14, 2013 · Pro- phylactic colectomy or proctocolectomy is indi- cated in these patients who are at very high risk of developing colon cancer [3, 4]. A ...
... mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in ...
... mucositis in patients receiving bolus 5-FU chemotherapy or high-dose melphalan. This intervention is consistent with the MASCC/ISOO guidelines published in ...
... patients in high level group responded to chemotherapy ... oral mucositis in patients after hematopoietic stem cell transplantation under intensive oral care N.
0751. THE RISK OF THROMBOCYTOPENIA AND NEUROPATHY AFTER BORTEZOMIB. THERAPY DEPENDS ON THE BASELINE PLATELET COUNTS AND PREVIOUS NEUROPATHY.